Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients
Frontiers in Immunology · 2026
DOI: 10.3389/fimmu.2025.1717543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Yandan Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Epitopes, T-Lymphocyte, Hepatitis B, Chronic, Hepatitis B virus, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims In our previous work, a total of 103 CD8 + T-cell epitopes restricted by 13 prevalent HLA-A allotypes in Northeast Asians were validated from the main proteins of hepatitis B virus (HBV). This study aims to further screen the T-cell epitopes restricted by 15 prevalent HLA-B and 14 prevalent HLA-C allotypes and establish a universal assay for counting reactive HBV-specific T cells in patients with chronic hepatitis B (CHB).
Methods
CD8 + T-cell epitopes were systematically screened through a combination of in silico prediction, ex vivo co-cultures of peptides with patient-derived peripheral blood mononuclear cells (PBMCs), and peptide competitive binding assays using HLA-B/C transfected cell lines.
Results
A total of 89 novel CD8 + T-cell epitopes were identified from four HBV main proteins using PBMCs from 250 CHB patients. Furthermore, 201 validated CD8 + T-cell epitope peptides restricted by the 13 HLA-A, 15 HLA-B, and 14 HLA-C allotypes were integrated to construct a broad-spectrum epitope peptide library, and by which the ELISpot assay was established followed by clinical testing for 81 CHB patients. The counts of reactive HBV-specific T cells and T cells reactive to each HBV protein (HBsAg-, HBpol-, HBx-, or HBeAg-) in PBMCs showed a negative correlation with serum HBsAg levels and no correlation with HBeAg or ALT levels. NUCs/IFN-α combination elicited significantly more reactive HBV-specific T cells (including those targeting HBsAg, HBpol, HBx, or HBeAg) than NUCs or IFN-α monotherapy.
Conclusions
The proposed method holds great potential for facilitating routine evaluation of HBV-specific CD8 + T cell reactivity in CHB patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.
- Department of Hepatitis, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Infectious Diseases, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Zitieren
APA
Wu, Y., Zhao, Y., Ji, R., Li, P., Chen, H., Yue, F., Wu, Y., Qiu, J., & Shen, C. (2026). Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1717543
Vancouver
Wu Y, Zhao Y, Ji R, Li P, Chen H, Yue F, et al. Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2025.1717543
BibTeX
@article{Wu2026,
author = {Wu, Yandan and Zhao, Yu and Ji, Ruixue and Li, Pinqing and Chen, Huijuan and Yue, Fangping and Wu, Yi and Qiu, Jie and Shen, Chuanlai},
title = {Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients},
journal = {Frontiers in Immunology},
year = {2026},
doi = {10.3389/fimmu.2025.1717543}
}
EUVIMED